Umbilical cord blood transplant with pooled stem cell product shows 96% survival and no graft-versus-host-disease in leukemia patients
A phase 2 study published in the Journal of Clinical Oncology shows that a stem cell product called dilanubicel safely enabled umbilical cord blood transplants in 28 patients A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A